BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
BioCardia, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in regulatory discussions with agencies in Japan and the U.S. The company achieved important milestones including PMDA support for CardiAMP Cell Therapy submission in Japan, FDA acknowledgement that the CardiAMP HF II trial …